BPC-157 Benefits: What the Research Actually Shows

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a protective sequence in human gastric juice. Preclinical research (predominantly rodent studies) suggests broad tissue-repair activity through upregulation of growth-hormone receptor expression, VEGF-driven angiogenesis, and modulation of the nitric-oxide system.

Research vial

$33 · 5mg vial

Buy now → $33

The 9 most-studied BPC-157 benefits

Evidence tiers below reflect the current literature — rodent, in-vitro, and limited human case reports. BPC-157 is not FDA-approved and is banned by WADA for competition.

Tendon-to-bone healing (Achilles, rotator cuff) — strong preclinical signal
Ligament and muscle-tear recovery — accelerated fibroblast migration
Gastrointestinal ulcer healing (esophageal, gastric, IBD models)
Joint pain and osteoarthritis — anti-inflammatory in cartilage models
Angiogenesis and wound closure via VEGFR2 pathway
Neuroprotection in TBI and stroke rodent models
Liver and hepatic protection against toxins
Reversal of NSAID- and corticosteroid-induced tissue damage
Blood-pressure normalization in rodent hypertension models

How BPC-157 works (mechanism of action)

BPC-157 upregulates growth-hormone receptors on fibroblasts and endothelial cells, accelerating tendon fibroblast proliferation and migration. It stimulates VEGF expression driving new capillary formation into damaged tissue, and it modulates the NO-system to protect endothelial function. This combination explains the "everywhere at once" repair signal seen in the literature.

Human evidence vs. rodent hype

The vast majority of BPC-157 studies are in rats. Published human data is limited to small case series and self-report. That gap is why BPC-157 remains research-use only in the United States and why any use must be discussed with a qualified clinician.

Typical research protocols

Peer-reviewed protocols most commonly report 200–500 mcg subcutaneously daily for 4–8 weeks. Oral and topical routes have been studied in animal models but bioavailability data in humans is sparse. See our full BPC-157 dosage guide for stack pairings.

Frequently asked questions

Is BPC-157 FDA approved?

No. BPC-157 is not FDA-approved for any indication. It is sold in the U.S. as a research chemical, and the FDA placed it on the 503A "do not compound" list in 2023.

How long until BPC-157 works?

Preclinical injury models show measurable healing within 5–14 days. Anecdotal human reports for tendon and gut symptoms describe a 2–4 week window at 250–500 mcg/day.

Does BPC-157 have side effects?

The peptide has an unusually clean safety profile in animals (no LD50 established). Reported human effects are mostly injection-site reactions, mild dizziness, and transient fatigue. Long-term human safety is unknown.

Can you stack BPC-157 with TB-500?

Yes — this is the "Wolverine stack" (BPC-157 + TB-500). BPC-157 drives angiogenesis and fibroblast repair while TB-500 (thymosin beta-4 fragment) accelerates cell migration and reduces scar tissue.

Keep researching

Protocol oversight provided by Kindr Health Inc. (NPI: 1609792902). Peptides sold through the Kindr research shop are for laboratory research use only and are not intended to diagnose, treat, cure, or prevent any disease.